Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort
Open Access
- 30 August 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 105 (7), 890-896
- https://doi.org/10.1038/bjc.2011.328
Abstract
This study aims to identify prognostic factors and to develop a risk model predicting survival in patients undergoing secondary cytoreductive surgery (SCR) for recurrent epithelial ovarian cancer. Individual data of 1100 patients with recurrent ovarian cancer of a progression-free interval at least 6 months who underwent SCR were pooled analysed. A simplified scoring system for each independent prognostic factor was developed according to its coefficient. Internal validation was performed to assess the discrimination of the model. Complete SCR was strongly associated with the improvement of survival, with a median survival of 57.7 months, when compared with 27.0 months in those with residual disease of 0.1–1 cm and 15.6 months in those with residual disease of >1 cm, respectively (P23.1 months, hazard ratio (HR): 1.72; score: 2), ascites at recurrence (present vs absent, HR: 1.27; score: 1), extent of recurrence (multiple vs localised disease, HR: 1.38; score: 1) as well as residual disease after SCR (R1 vs R0, HR: 1.90, score: 2; R2 vs R0, HR: 3.0, score: 4) entered into the risk model. This prognostic model may provide evidence to predict survival benefit from secondary cytoreduction in patients with recurrent ovarian cancer.Keywords
This publication has 29 references indexed in Scilit:
- Surgery in recurrent epithelial ovarian cancer: Benefits on Survival for patients with residual disease of 0.1–1 cm after secondary cytoreductionJournal of Surgical Oncology, 2010
- Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: A phase II studyGynecologic Oncology, 2009
- Multiple imputation in a large-scale complex survey: a practical guideStatistical Methods in Medical Research, 2009
- Missing Data Analysis: Making It Work in the Real WorldAnnual Review of Psychology, 2009
- The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancerAnnals Of Oncology, 2008
- Use of Multiple Imputation in the Epidemiologic LiteratureAmerican Journal of Epidemiology, 2008
- Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200)Gynecologic Oncology, 2008
- Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: Who benefits?Cancer, 2004
- Cytoreductive Surgery in Ovarian Carcinoma Patients with a Documented Previously Complete Surgical ResponseGynecologic Oncology, 1995
- Secondary cytoreductive surgery for recurrent epithelial ovarian cancerGynecologic Oncology, 1989